The t(14;18)(q32;q21) translocation is closely associated with follicular lymphoma (FL), and is routinely assessed with molecular methods exploring BCL2 breakpoints for both diagnosis and minimal residual disease (MRD) monitoring. We and others have previously reported new recurrent breakpoints (3ЈBCL2 and 5Јmcr) which could be easily analyzed. In this study, we characterized the BCL2 breakpoints in 113 untreated patients with t(14;18)-positive FL and correlated their location with the location of JH break and with the clinical features. Breakpoints were respectively located at the major breakpoint region (MBR) in 73 cases (65%), at the minor cluster region (mcr) in 10 cases (9%), at 3ЈBCL2 in 14 cases (12%) and at 5Јmcr in seven cases (6%). Finally, the breakpoint could not be located in nine patients (8%). 5Јmcr cases were associated with bulky and high-stage disease, with frequent extranodal involvement and bone marrow infiltration. Survival studies did not show any correlation between breakpoint location and clinical outcome. The joining JH6 segment was the most frequently involved whatever the breakpoint location. In conclusion, unusual BCL2 breakpoints are found in about 20% of newly diagnosed follicular lymphomas and their study should be considered in the investigation of BCL2-JH rearrangement. It was not possible, in this series, to demonstrate any correlation between breakpoint location and either initial characteristics of the disease or survival of the patients.
Introduction
Within the wide spectrum of non-Hodgkin's lymphomas (NHL), follicular lymphoma (FL) appears as an homogeneous entity according to its clinical and histological features. Derived from germinal centre (GC) B cells, it is closely associated with the t(14;18)(q32;q21) recurrent translocation, involving the IGH locus at 14q32 and BCL2 at 18q21. 1 The BCL2-JH rearrangement represents a marker which can be analyzed using molecular techniques for diagnosis and monitoring of minimal residual disease (MRD). 2 Sixty percent of BCL2 breakpoints are located at the major breakpoint region (MBR) in the 3Ј non-coding part of the third exon, and 5 to 25% at the minor cluster region (mcr), 20 kb downstream of the gene. [3] [4] [5] Rare breakpoints are found in the 5Ј part of the gene (variant cluster region, vcr) and involve immunoglobulin light chain variant translocations. 6 Recently, using new PCR techniques, we and others [7] [8] [9] have reported new clusters between MBR and mcr, referred to as 3ЈBCL2 and 5Јmcr.
It has to be admitted that the presence of a t(14;18) has no prognostic value by itself in FL, 10, 11 but a recent study reported that the BCL2-JH rearrangement location could be correlated to the disease outcome. 12 On the other hand, molecular characterization of JH segments in B cell recurrent IGH translocations suggests that a specific JH usage may correspond to a specific state of B cell maturation. 13, 14 The aim of this study was to characterize BCL2 breakpoint location and JH segments usage in a large series of patients with untreated FL with a 14;18 translocation and to correlate these characteristics with initial clinical features and disease outcome.
Materials and methods

Patients
One hundred and thirteen patients with untreated FL were retained for this study. All had a 14;18 translocation upon lymph node cytogenetic analysis. For 100 cases, the quantity of lymph node material was sufficient for histological, cytogenetic and molecular analysis whereas for 13 cases, molecular analysis was achieved on bone marrow aspirates. Patients were diagnosed and treated in the Department of Hematology of the Centre Henri Becquerel, Rouen, France from 1984 to 2000.
Histology
All lymph nodes biopsies were analyzed in our institution using conventional examination of paraffin-embedded tissue. Immunohistochemical complementary studies were performed on frozen or on paraffin-embedded sections. Cases were retrospectively classified according to the WHO criteria. 15 
Cytogenetic analysis
Methods for cytogenetic analysis have been previously reported. 16 Karyotypes were described according to the International System for Human Cytogenetic Nomenclature. 17 
DNA samples
High molecular weight DNA was extracted from lymph node biopsy or bone marrow aspirates using proteinase K digestion, saturated NaCl extraction and ethanol precipitation.
PCR analysis of BCL2-JH rearrangement
All samples were tested for BCL2-JH rearrangement with usual MBR and mcr primers but also as previously described 7 for the 3ЈBCL2 subcluster. According to previous data on mcr region, 9 new primers were designed for the 5Јmcr cluster (Biomed II concerted action PL 96 3936, manuscript in preparation). PCR products (20 l) were analyzed by 1.5% agarose gel electrophoresis (SeaKem GTG agarose, FMC Bioproducts, Rockland, ME, USA) and visualized under UV illumination after ethidium bromide staining.
PCR analysis of JH segment
JH-specific primers combined with BCL2-specific primers were used to characterize the specific JH segment used in each BCL2-JH translocation, as previously described by Verhagen et al. 18 JH primers were as follow: JH1 (5Ј-GCC TAT CCC CAG ACA GCA GA-3Ј), JH2 (5Ј-GGT GCC TGG ACA GAG AAG ACT-3Ј), JH3 (5Ј-AGG CAG AAG GAA AGC CAT CTT AC-3Ј), JH4 (5Ј-CAG AGT TAA AGC AGG AGA GAG GTT GT-3Ј), JH5 (5Ј-AGA GAG GGG GTG GTG AGG ACT-3Ј), JH6 (5Ј-GCA GAA AAC AAA GGC CCT AGA GT-3Ј) (GensetOligos; Genset, Paris, France). Reaction mixture consisted of 100 ng DNA, 5 l 10 × buffer (Amersham Pharmacia Biotech, Cleveland, OH, USA), 200 mol/l of each dNTP, 50 pmol of each primer and 2.5 U Taq DNA polymerase (Amersham Pharmacia Biotech). Amplification protocol was: initial denaturation 10 min at 94°C followed by 34 cycles of 1 min denaturation, 1 min annealing at 60°C and 1 min 30 s extension at 72°C. Final extension was achieved for 10 min at 72°C and the temperature was then held at 4°C. As for the BCL2-JH analysis, 20 l of PCR products were analyzed by 1.5% agarose gel electrophoresis (Seakem GTG agarose, FMC Bioproducts) and visualized under UV illumination after ethidium bromide staining (Figure 1 ).
Statistical analysis
Clinical characteristics and molecular findings were tabulated and compared using the chi-square test. Overall survival (OS) was calculated from the date of diagnosis to the date of death or to the last available follow-up date for living patients. Survival curves were plotted using the method of and were compared by the log-rank test. 20 Ninety-five percent confidence intervals were determined as described by Rothman.
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Results
Patients
Data are summarized in Table 1 . The median age of patients was 53 years (range 28 to 82). Men represent 50% of the total population (56/113). The distribution according to the WHO classification was: FL grade I, 72 cases (64%); grade II, 32 cases (28%) and grade III, nine cases (8%). Fourteen patients (12%) presented with Ann Arbor stage I, 13 (11%) with stage II, 31 (27%) with stage III and 55 (49%) with stage IV. Bulky disease (tumor diameter larger than 7 cm) was present in 39% of the cases (44/113), extranodal involvement of more than one site in 48% (54/113) and bone marrow infiltration was found in 42% (48/113) of the cases. An elevated serum lactate dehydrogenase (LDH) level (Ͼ1 N) was found in 34% (34/101) and a high beta2-microglobulin (Ͼ1 N) in 28% of patients (19/42).
Leukemia
Figure 1
JH segment analysis. (a) Agarose gel electrophoresis (ethidium bromide staining) of PCR products obtained in four patients using JH3-to JH6-specific primers: the breakpoint involves JH6 for samples 1 and 2 and JH4 for samples 3 and 4. (b) Representation of a MBR-JH4 rearrangement: three specific JH primers are able to generate a MBR-JH product.
Breakpoint location
Using conventional primers, breakpoints in BCL2 were found at MBR in 73 patients (65%) and at mcr in 10 patients (9%). New primer sets allowed breakpoint assignment at 3ЈBCL2 in 14 patients (12%) and at 5Јmcr in seven patients (6%). Finally, nine samples (8%) remained negative with all primers used in our laboratory.
PCR analysis of JH segment
JH segments involved in BCL2-JH rearrangement were studied in 91/104 BCL2 rearranged cases (Table 2) (Figure 1 ). Whatever the BCL2 breakpoint, the JH6 segment was the most frequently involved (55%); JH5 was found almost as frequently as JH4 (19% and 23% respectively). JH3 involvement was very rare (2/91) and no JH1 or JH2 rearrangement was found in the whole series. No statistical correlation could be observed between JH usage, breakpoint location, clinical features or clinical outcome (data not shown). 
Correlation between BCL2 breakpoint location and clinical features
Data are summarized in Table 1 . No significant difference was found in the distribution of clinical features depending on the breakpoint location group. However, 5Јmcr patients tented to have bulky and disseminated diseases, with frequent extra nodal involvement and bone marrow infiltration. Conversely, LDH and beta-2 microglobulin levels were slightly increased in the mcr group.
Overall survival
No statistical difference in OS could be observed between the different groups of patients according to breakpoint location. Estimated OS at 3 years from diagnosis was 78% (95% confi-
Figure 2
Survival curves according to breakpoint locations.
dence interval (CI): 69-85) for the whole population ( Figure  2 ), and respectively 75% (CI: 63-84) for the group with the break at the MBR, 78% (CI: 49-94) for the mcr group, 91% (CI: 64-98) for the 3ЈBCL2 group, 68% (CI: 32-91) for the 5Јmcr and 86% (CI: 53-98) for cases where no breakpoint location could be demonstrated (Figure 2 ).
Discussion
Recently, Lopez-Guillermo et al 12 reported that there was a correlation between BCL2 breakpoint location, as determined using PCR methods identifying MBR and mcr rearrangements, and the clinical behavior in FL patients. On the other hand, we and others reported new recurrent breakpoint clusters in FL. 7, 9 In this study, we aimed to determine the relative frequency of all identified BCL2 breakpoint locations in a series of 113 untreated t(14;18)-positive FL patients, and to analyze the corresponding clinical features and prognostic significance. As all patients had a t(14;18), as assessed by chromosomal analysis, only non-amplifiable translocations (located outside any explored region) could account for negative PCR results and not either a light chain variant translocation or a FL associated with any other abnormality that could contribute to the PCRnegative population in the Lopez-Guillermo study. 12 No correlation between BCL2 breakpoint and disease grading could be observed in this series, whereas such a correlation was previously reported for MBR and mcr breakpoints. 12 No significant differences could be evidenced regarding clinical characteristics according to breakpoint location, although some tendencies can be noted, mainly a more aggressive clinical presentation in the group of patients with a breakpoint at 5Јmcr.
No correlation could be evidenced between survival and breakpoint location in these patients. This could be explained in part by the fact that all patients retained in the present study had a proven 14;18 translocation, representing a more homogeneous FL population, and that 3Ј BCL2 and 5Ј mcr breaks were explored whereas they were reported as being negative in Lopez-Guillermo molecular assays.
In the present study, unusual BCL2 breakpoints were observed in about 20% of the cases. Therefore, the number of t(14;18)-positive but PCR-negative patients was reduced to less than 10% instead of the 30% observed with usual primers in an unselected population. 22 In a previous study using longdistance PCR, Akasaka et al. 9 were able to amplify all BCL2-JH rearrangements in a FL/diffuse large B cell lymphomas series. The use of such PCR methods 8, 9 should allow all PCR-negative remaining cases to be resolved.
Comparison of various JH segment usage between lymphomas and normal B cell has been already reported.
14 JH4 is known to be used in the normal B cell repertoire, 23, 24 while JH6 is mainly used in GC derivative FL cells. 9, 13, 25 Moreover, use of distinct JH segments in mantle cell lymphomas and FL may account for differences in the mechanism leading to the occurrence of a translocation in early B cells. 14, 26 In our series, the JH6 segment was the most frequently involved (55%) whatever the BCL2 breakpoint location.
In conclusion, breakpoints located outside the MBR and mcr regions can be found in about 20% of newly diagnosed FL and their specific study should be included in the PCR strategies aiming to analyze BCL2-JH rearrangement. It was not possible, in this series, to demonstrate any correlation between breakpoint location, JH usage, initial characteristics or outcome of the disease. Altogether, these findings are consistent with the absence of specific molecular subtypes of 14;18-positive FL.
